Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy

Autor: Henrique Tria Bianco, Carolina Nunes França, Simone P. Barbosa, Francisco Antonio Helfenstein Fonseca, L.M. Camargo, Mco Izar, L.S. Lins, Luiz Fernando Muniz Pinheiro
Přispěvatelé: Universidade Federal de São Paulo (UNIFESP)
Rok vydání: 2014
Předmět:
Male
CD31
Simvastatin
Platelet Aggregation
Physiology
CD34
Coronary Disease
Pharmacology
Biochemistry
Cell-Derived Microparticles
Platelet aggregation
Platelet
General Pharmacology
Toxicology and Pharmaceutics
lcsh:QH301-705.5
Endothelial progenitor cells
lcsh:R5-920
Aspirin
Anticholesteremic Agents
General Neuroscience
General Medicine
Middle Aged
Flow Cytometry
Clopidogrel
Drug Combinations
Platelet microparticles
Female
lcsh:Medicine (General)
medicine.drug
medicine.medical_specialty
Ticlopidine
Immunology
Biophysics
Simvastatin/ezetimibe
Ocean Engineering
Ezetimibe
medicine
Humans
Clinical Investigation
Progenitor cell
Triglycerides
Aged
business.industry
Cholesterol
LDL
Cell Biology
Surgery
lcsh:Biology (General)
Azetidines
Endothelial microparticles
business
Platelet Aggregation Inhibitors
Zdroj: Brazilian Journal of Medical and Biological Research, Volume: 47, Issue: 5, Pages: 432-437, Published: 15 APR 2014
Repositório Institucional da UNIFESP
Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
Brazilian Journal of Medical and Biological Research
Brazilian Journal of Medical and Biological Research, Vol 47, Iss 5, Pp 432-437 (2014)
Brazilian Journal of Medical and Biological Research v.47 n.5 2014
Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
ISSN: 1414-431X
0100-879X
DOI: 10.1590/1414-431x20143628
Popis: It is not known whether the addition of ezetimibe to statins adds cardiovascular protection beyond the expected changes in lipid levels. Subjects with coronary heart disease were treated with four consecutive 1-week courses of therapy (T) and evaluations. The courses were: T1, 100 mg aspirin alone; T2, 100 mg aspirin and 40 mg simvastatin/10 mg ezetimibe; T3, 40 mg simvastatin/10 mg ezetimibe, and 75 mg clopidogrel (300 mg initial loading dose); T4, 75 mg clopidogrel alone. Platelet aggregation was examined in whole blood. Endothelial microparticles (CD51), platelet microparticles (CD42/CD31), and endothelial progenitor cells (CD34/CD133; CDKDR/CD133, or CD34/KDR) were quantified by flow cytometry. Endothelial function was examined by flow-mediated dilation. Comparisons between therapies revealed differences in lipids (T2 and T3T1 and T4, P=0.001). Decreased platelet aggregation was observed after aspirin (arachidonic acid, T1
Databáze: OpenAIRE
Externí odkaz: